Astria Therapeutics (ATXS) News Today $6.18 -0.35 (-5.39%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $29.00August 29 at 2:05 AM | americanbankingnews.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of "Buy" from BrokeragesAugust 28 at 3:10 AM | marketbeat.comAstria Therapeutics to Present at Upcoming Cantor Global Healthcare ConferenceAugust 27 at 8:31 AM | mms.businesswire.comAstria Therapeutics (NASDAQ:ATXS) Stock Crosses Above 50-Day Moving Average - Here's WhyAugust 22, 2025 | marketbeat.comEquities Analysts Set Expectations for ATXS FY2025 EarningsAugust 17, 2025 | marketbeat.comHC Wainwright Issues Optimistic Forecast for ATXS EarningsAugust 17, 2025 | marketbeat.comQ3 Earnings Estimate for ATXS Issued By Lifesci CapitalAugust 17, 2025 | marketbeat.comQ3 EPS Estimates for Astria Therapeutics Boosted by WedbushAugust 17, 2025 | marketbeat.comQ4 Earnings Estimate for ATXS Issued By Lifesci CapitalAugust 16, 2025 | marketbeat.comJMP Securities Issues Positive Forecast for Astria Therapeutics (NASDAQ:ATXS) Stock PriceAugust 15, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Astria Therapeutics (NASDAQ:ATXS)August 15, 2025 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Issues Earnings Results, Beats Expectations By $0.04 EPSAugust 14, 2025 | marketbeat.comAstria Therapeutics price target raised to $26 from $25 at Citizens JMPAugust 13, 2025 | msn.comAstria Therapeutics Reports Increased Losses Amid R&D ExpansionAugust 12, 2025 | tipranks.comAstria Therapeutics reports Q2 EPS (57c), consensus (58c)August 12, 2025 | msn.comAstria Therapeutics (NASDAQ:ATXS) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?August 10, 2025 | marketbeat.comAstria Therapeutics (ATXS) to Release Earnings on MondayAugust 5, 2025 | marketbeat.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 | businesswire.comAstria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE PatientsAugust 1, 2025 | msn.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of "Buy" from AnalystsAugust 1, 2025 | marketbeat.comAstria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National SummitJuly 7, 2025 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of "Buy" by AnalystsJuly 7, 2025 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Pass Above Fifty Day Moving Average - Should You Sell?July 5, 2025 | marketbeat.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Seeking AlphaJuly 3, 2025 | seekingalpha.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMATXS - Astria Therapeutics Inc Key Metrics - MorningstarJuly 2, 2025 | morningstar.comMAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | businesswire.comAstria Therapeutics Inc News (ATXS) - Investing.comJune 25, 2025 | investing.comAstria Therapeutics (NASDAQ:ATXS) Shares Cross Above Fifty Day Moving Average - Here's WhyJune 21, 2025 | marketbeat.comAstria Therapeutics' (ATXS) Buy Rating Reiterated at HC WainwrightJune 13, 2025 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Buy" from AnalystsJune 12, 2025 | marketbeat.comEquities Analysts Set Expectations for ATXS FY2026 EarningsJune 10, 2025 | marketbeat.comAstria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual CongressJune 6, 2025 | businesswire.comAstria Therapeutics at Jefferies Conference: Strategic Pipeline InsightsJune 6, 2025 | investing.comAstria Therapeutics to Present at Upcoming Jefferies Global Healthcare ConferenceMay 28, 2025 | finance.yahoo.comAstria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema WorkshopMay 23, 2025 | businesswire.comAstria Therapeutics to Present at Upcoming Eastern Allergy ConferenceMay 22, 2025 | businesswire.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Shares Sold by VR Adviser LLCMay 22, 2025 | marketbeat.comVestal Point Capital LP Acquires 180,000 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)May 21, 2025 | marketbeat.comPatient Square Capital LP Boosts Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)May 16, 2025 | marketbeat.comAstria Therapeutics Shares Rise Following Update on In-Development DrugsMay 13, 2025 | marketwatch.comAstria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 13, 2025 | businesswire.comFcpm Iii Services B.V. Purchases New Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)May 11, 2025 | marketbeat.comIs Astria Therapeutics, Inc. (ATXS) the Low Risk High Reward Stock Set to Triple by 2030?May 10, 2025 | insidermonkey.comRaymond James Financial Inc. Buys Shares of 79,044 Astria Therapeutics, Inc. (NASDAQ:ATXS)May 9, 2025 | marketbeat.comInvesco Ltd. Has $161,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)May 6, 2025 | marketbeat.comCantor Fitzgerald Comments on ATXS FY2025 EarningsMay 3, 2025 | marketbeat.comAstria Therapeutics (ATXS) to Release Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comAstria Therapeutics reports progress in HAE drug trialMay 2, 2025 | investing.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | businesswire.com Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATXS Media Mentions By Week ATXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATXS News Sentiment▼1.021.03▲Average Medical News Sentiment ATXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATXS Articles This Week▼43▲ATXS Articles Average Week Get the Latest News and Ratings for ATXS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Astria Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Schrodinger News Today Avadel Pharmaceuticals News Today Ardelyx News Today Janux Therapeutics News Today Harrow News Today Vera Therapeutics News Today Amphastar Pharmaceuticals News Today Syndax Pharmaceuticals News Today 89BIO News Today Cogent Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATXS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access